**Xpert MTB/RIF Testing Quality Indicators (Monthly Report)**

These indicators should be monitored and analysed by the testing laboratory and reported to the supervisory laboratory monthly. (See XXX for Excel data collection tool template).

|  |
| --- |
| Site Name |
| District |
| Name of person compiling this report |
| Reporting period (Month/Year) |

|  |  |  |
| --- | --- | --- |
| **Total Numbers (combined data for all instruments at one testing site)** | | |
| Number of specimens tested with Xpert MTB/RIF  (Disaggregate by HIV status, MDR risk, extra-pulmonary TB) | A |  |
| Number of specimens with MTBC not detected | B |  |
| Number of specimens with MTBC detected rifampicin resistance not detected | C |  |
| Number of specimens with MTBC detected rifampicin resistance detected | D |  |
| Number of specimens with MTBC detected rifampicin indeterminate | E |  |
| Number of specimens with MTBC detected trace (Ultra only) | F |  |
| Number of specimens with errors | G |  |
| Number of specimens with invalid results | H |  |
| Number of specimens with no results | I |  |
| Number of specimens tested with Xpert MTB/RIF for which a result was reported within 24 hours | J |  |
| Number of functional GeneXpert modules (GX4 = 4 modules etc.) | K |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **Analysis** | | | |
| **Indicator** | **Formula** | **Result** | **Target** |
| Number of specimens with MTBC detected | C+D+E+F |  | Dependent on population tested and TB prevalence | |
| % specimens with MTBC detected, rifampicin resistance not detected | [C/A]x100 |  | Dependent on population tested and drug-resistance prevalence | |
| % specimens with MTBC detected, rifampicin resistance detected | [D/A]x100 |  | Dependent on population tested and drug-resistance prevalence | |
| % specimens with MTBC detected rifampicin indeterminate | [E/A]x100 |  | Dependent on population tested and drug-resistance prevalence | |
| % specimens with MTBC detected trace, disaggregated by patient group (Ultra only) | [F/A]x100 |  | Dependent on population tested and drug-resistance prevalence | |
| % specimens with MTBC not detected | [B/A]x100 |  | Dependent on population tested and TB prevalence | |
| % specimens with errors | [G/A]x100 |  | <3% | |
| % specimens with invalid results | [H/A]x100 |  | <1% | |
| % specimens with no results | [I/A]x100 |  | <1% | |
| % specimens for which a result was reported within 24hr (i.e., time from receipt of specimen to reporting) | [J/A]x100 |  | >95%. The target turnaround time may be modified by the programme | |
| Maximum Xpert testing capacity per month at this site (3 test per module times 20 working days) | K×3x20 |  | Full utilization of a 4-module GeneXpert instrument is 12 tests per workday | |
| % Maximum instrument capacity being utilized | [A/(K×3× 20)]x100 |  | Target is setting specific | |

|  |  |  |  |
| --- | --- | --- | --- |
| **Operational issues and modules failures** | | | |
| Number of days of routine Xpert service interruption this month |  |  | No interruptions |
| Reason(s) for service interruption |  |  | |
| Number of stock outs leading to service interruption |  |  | No interruptions |
| Number of instances of equipment downtime and duration of each instance |  |  | No interruptions |

|  |  |  |
| --- | --- | --- |
| **Proficiency testing (PT) (update quarterly or semiannually)\_** | | |
| Date of completion of last proficiency test |  |  |
| Date of receipt of PT score |  |  |
| Score achieved during the last completed round of PT |  |  |